Royal Philips and Medtronic Neurovascular announced a strategic advocacy partnership to raise awareness about the health and economic benefits of timely stroke diagnosis and treatment. Their collaboration aims to improve access to stroke care for patients, families, and communities worldwide.
The companies have expanded their partnerships with the World Stroke Organization (WSO) by joining the newly established WSO Advocacy Coalition. This coalition unites healthcare professionals, patient groups, and policymakers to develop strategies addressing the global burden of stroke. Together, Philips and Medtronic are working with WSO to share research, exchange best practices, and promote policy advancements in stroke care.
The partnership focuses on three key areas:
1. Raising Awareness: Promoting public understanding of stroke symptoms and the need for urgent care.
2. Improving Access to Treatment: Increasing the number of stroke-ready hospitals and training healthcare professionals in advanced techniques.
3. Leveraging Technology: Utilizing advanced imaging and digital tools to integrate stroke care systems for early diagnosis, effective treatment, and rehabilitation.
The initiative will be featured at the World Stroke Congress (WSC), held from October 23–26 in Abu Dhabi, where Philips and Medtronic will host a Stroke Advocacy roundtable session. The partnership builds on their efforts at global forums like the United Nations General Assembly (UNGA) and World Health Assembly, where they advocated for investments in stroke care infrastructure.
“Stroke care is a race against time,” said Signe Haughton, senior director of medical and government affairs at Medtronic Neurovascular. “By joining forces with Philips, we aim to accelerate access to life-saving treatments like mechanical thrombectomy.”
At the recent UNGA event, leaders emphasized the need to address disparities in stroke care, highlighting that access to timely intervention, prevention, and rehabilitation is essential to reducing the burden of stroke, the world’s second leading cause of death.